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Abstract The vision of the future health care should be 
a system in which patient care is consistently improved 
through the use of information on the individual patient’s 
genomes and their downstream products. This requires 
the exploration of strategic relationships among various 
disciplines  such  as  life  sciences,  mathematics,  physics, 
chemistry, and information and communication technol-
ogy, and constellation thinking to propose new ways for 
the diagnosis and therapy of diseases, integrated with a 
planned  trans-disciplinary  scientific  approach  involving 
all  interested  parties.  Connecting  high-quality  trans-dis-
ciplinary scientists on a pan-European level through pro-
grams such as the Cooperation in Science and Technology 
(COST) can support capacity building and increase the im-
pact of personalized medicine research on regulatory bod-
ies, decision makers, pharmaceutical and insurance com-
panies, and the paying public. Such group effort could 
enable breakthrough scientific developments leading to 
new concepts and products and thereby contributing to 
the strengthening of Europe’s research and innovation ca-
pacity while reforming the health care system.
Basic science on the genetic background of individual re-
ceptiveness toward drugs has progressed over the years. 
Differences in metabolic capacity have been for example in 
the focus of the first the Cooperation in Science and Tech-
nology action in biomedicine (COST B1, 1986). Since then, 
progress has been made in the research on the pharmaco-
dynamic aspect to clarify individual vulnerability. Lately, ad-
ditional progress has been made owing to innovative tools 
for diagnosis at the molecular level, leading steadily into 
a transformation of the health care system; a transforma-
tion fueled by the adoption and the rapid developments 
of information and communication technology (ICT), ge-
nomics and related disciplines, as well as the cultural driv-
ers of personalized medicine (1). The virtual patient model 
enabled by personalized ICT services and providing genet-
ic and genomic information of every individual based on 
a laboratory-on-chip technology and bio-nanotechnology 
promises personalized medication and genome profiles 
and other “-omics” of individuals (2). Personalized medical 
care is designed to get the individual patient a drug that 
will be therapeutically active while minimizing the adverse 
effects.
Personalized medicine encompasses not only tailor-made 
drugs at the correct dose for the right patient, but also in-
corporates management of our personal data and clini-
cal information (3). Realizing the potential of personalized 
medicine requires new methods for processing of the del-
uge of genomic data and translation of the findings into 
medical  practice  (2).  Biology  is  being  captured  in  soft-
ware and hardware through the modeling of genes, pro-
teins, cells, and human organs. This theoretical abstraction 
of biology into accurate models involves the disciplines of 
mathematics, physics, and chemistry, while data gathering, 
simulation, and visualization are involving all aspects of ICT. 
The upheaval in the life sciences enabled by ICT requires 
new  computing  capabilities,  sophisticated  algorithms,  a 
vast range of software products, internet technologies, as 
well  as  advanced  data  management  capabilities  for  the 
large  torrent  of  data. The  creation  of  the  virtual  patient 
model, a personal simulation of the human body becomes 
mandatory for a faster, reliable, and successful health care 
system. The  development  of  affordable  next-generation 
high-throughput technologies allows generation of data 
from the entire genome, transcriptome, epigenome, etc, 
from a single (routine) clinical specimen (4,5). These tech-
nologies are expected to influence the fundamentals of the 
current practice of “reactive” medicine to a more systemic, 
structured, and evidence-based approach, to change the 
current classification/definition of disease entities and to 
influence to a great extent the therapeutic protocols. As 
a consequence, ICT is a fundamental part of the process 
of understanding the human body and life in itself as a 
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drug discovery/development process, providing new tar-
gets for selective inhibitors, and reducing costs.
The appropriate use of ICTs is probably the most important 
strategy  to  translate  information  from “-omics”  research 
into clinically relevant products and technologies and rev-
olutionize life sciences.
ChaLLengeS and opportunitieS
The  numerous  challenges  faced  by  scientists  slow  the 
progress in personalized medicine, subsequently delaying 
the advantages and the opportunities for the patients.
Identifying each individual’s reaction for absolute person-
alized medicine is neither easy and straightforward from a 
research perspective nor practical from a pharmaceutical, 
diagnostic, or prognostic perspective. Stratification of the 
patients’ responses within groups might be more practical 
and manageable as a first step to personalized medicine 
before we are technologically and scientifically advanced 
to  apply  personalized  medication.  Several  initiatives  in 
Europe including the UK’s Stratified Medicine Innovation 
Platform (6), Sweden’s Biobank Program (7), BIOMEDREG 
in Czech Republic (8), and the Munich Biotech Cluster are 
already working toward this goal (9). The US Food and 
Drug Administration is in the process of evaluating medi-
cal products and integrating the various medical product 
regulatory authorities provided by Congress in the Federal 
Food, Drug and Cosmetic Act to develop effective mecha-
nisms for successful implementation of personalized med-
icine in the USA (10).
In addition to the scientific challenges faced by scientists, 
several other issues have to be addressed for a triumphant 
implementation of this new health care system brought 
upon us by personalized medicine.
Well trained and educated personnel are required to de-
sign, maintain, and use these environments, which employ 
a whole new approach for the drug development process, 
providing new and validated drug targets for the devel-
opment of drugs with a much higher therapeutic success 
rate, safety, and further cost efficiency (11). The education 
of medical practitioners and the public as a whole on these 
new developments remains a formidable challenge.
We  are  empowering  the  patients  with  predictive  and 
preemptive information to manage their own health. 
They will be able to harness the knowledge to keep 
on being healthy or take advantage of treatments tailored 
to their genetic profile. On the other hand, these predictive 
abilities might make one decide that this is not a welcome 
method as individuals will have the power to know ahead 
of time whether they are susceptible to certain diseases 
based on their genetic profile (12). And what about privacy 
issues? Parents can decide at an early age that their child 
is to have a genetic profile. As an adult, that child might 
not want to know what awaits him/her in the future. This 
raises another question – how do we interpret prognostic 
information and what do we actually want to predict and 
where to intervene? Especially for children, a wrong prog-
nosis/interpretation  will  generate  serious  problems  that 
will follow him/her for the rest of his/her life.
Is this foretelling information going to be the privilege of 
the few? Are we going to end up with a health care sys-
tem that will not be accessible to everybody? Will the pa-
tient gain from the new approach when clinically ben-
eficial new products and procedures are translated into 
affordable clinical practice? The policy challenges, includ-
ing encouraging and financing innovation related to the 
field, need to be surmounted for effective individually tai-
lored medical interventions, simultaneously reforming the 
health care system.
Stratified medicine and the potential use of biomarkers 
are foreseen to have a major effect on both clinical prac-
tice and the development of new drugs and diagnostics 
(11-14)). The approach of therapies being matched with 
specific patient population characteristics uses clinical bio-
markers. This transforms product development strategies 
and market structures, having a strategic and economic 
impact on the whole health care system. Addressing the 
salient issues facing personalized medicine underpins the 
regulatory framework that governs it and the markets that 
drive its development and adoption. The major obstacles 
for making personalized medicine available to patients re-
quires basic, translational, and also regulatory science, es-
pecially in the areas of ethical, legal, and social issues (3). 
The vision should be a health care system in which pa-
tient care is consistently improved through the use of in-
formation on the individual patient’s genomes and their 
downstream products (ie, transcriptomes, proteomes, and 
metabolomes). This will require the exploration of strate-
gic  relationships  among  all  interested  parties  including 
researchers, clinicians, policy makers, and pharmaceutical 
and insurance companies. Constellation thinking will offer 
new ways for the diagnosis and therapy of diseases, inte-
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es, involving various disciplines, such as life sciences, math-
ematics,  physics,  chemistry,  and  ICT. Through  programs 
such  as  COST,  high-quality  trans-disciplinary  scientists 
should be connected to support capacity building, and 
research on regulatory bodies, decision makers, and phar-
maceutical and insurance companies. Only interdisciplin-
ary activities will enable breakthrough scientific develop-
ments leading to new concepts and products and thereby 
contributing to strengthen Europe’s research and innova-
tion capacities while simultaneously reforming the health 
care system.
Personalized medicine should not be a promise for the fu-
ture, but a common scientific and technological effort of-
fering patients and health care practitioners up-to-date di-
agnostics and therapeutics.
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